ONCOdianova – The Future of Biomarkers
ONCOdianova‘s antibody development program concentrates on the tissue-based detection of cancer immunology checkpoint biomarkers. Our vision is to provide the best primary antibodies for combined use in multiplex IHC panels.
Multiplex antibody IHC assay will allow to carefully identify what cell expresses the target, not just whether the target is present. The complexities of inhibitory immune checkpoint pathways along with the interplay of the tumor cells, the microenvironment and systemic immune parameters offer opportunities for research and clinical translation into immunotherapy. We believe that IHC-assessment of predictive immune checkpoint targets in tumor tissues will be crucial and indispensable to select patients and differentiating drugs to optimal guide treatment by immunotherapy.
ONCOdianova – Immunotherapy & Diagnostics
Despite intense efforts in the last several decades to improve treatment of advanced cancer, even the best cytotoxic regimens only rarely cure late stage malignancy. Today the clinical success of novel therapeutic strategies complementing and enhancing the bodies existing antitumor immune responses indicate a greater opportunity than a cytotoxic approach to potentiate durable remission.
The most powerful emerging trend in immunotherapy of cancer is encouraged by the clinical success of immune checkpoint inhibitors. Unlocking the immune response by blockade of inhibitory immune receptors with monoclonal blocking antibodies has revolutionized the treatment and survival prospects of cancer patient. The approval of the CTLA-4 blocker ipilimumab as well as blocking antibodies against PD-1 (nivolumab, pembrolizumab) or its ligand PD-L1 (atezolizumab, avelumab, durvalumab) have given proof of the enormous potential inherent to immune checkpoint blockade in cancer treatment. Only in the last decade Oncology recognized that the immune centered approach may be superior to the cytotoxic approach dominating cancer treatment for a long time. Immunotherapy hast joint the conventional big three chemotherapy, radiotherapy, and surgery as an equitable pillar in cancer treatment.
Hundreds of ongoing clinical trials in various cancer types explore checkpoint inhibitors in single-agent or combination treatment or combined with existing targeted cancer therapies, vaccines or classical therapeutic interventions. Promising results boost the identification of novel immune checkpoints as well as the development of antibody drugs against newly identified immune receptors and their ligands, like members of the PVR/ nectin superfamily around TIGIT signalling, B7 or SLAM family members or interactors of the LIGHT pathway.
However, the spectrum of inflammatory side effects (immune-related adverse events (irAEs)) associated with immune checkpoint therapies require a careful selection of patients who can profit form a specific immunotherapy. Diagnostic markers and pathways of classical pathology might not be sufficient for the characterization of therapy responsive patients.
Several new parameters have been suggested to determine the patients suitability to respond to a specific immunotherapy with immune checkpoint inhibitors, including the determination of tumor infiltrating lymphocytes (ImmunoScore, Galon 200x) or the quantification of PD-1/ PD-L1.
Cellular and molecular characterization of the tumor microenvironment will be the major challenge of future diagnostic methods to identify a patients tumor microenvironment immune status. Molecular diagnostic tests and sequencing methods may provide a multitude of data sets but they can not display the expression level, expression pattern, and spatial relationship of multiple biomarkers on immune cells in the histomorphological context of the local tumor microenvironment. This is a major advantage of quantitative pathology imaging techniques and multiplex immunohistochemistry. ONCOdianova designs antibodies to serve the rising field of immunohistochemical analysis of tumor microenvironment immune status. ONCOdianovas antibodies have been validated on a broad range of tumor tissues and selected for high precision detection of biomarkers in formalin-fixed paraffin embedded (FFPE) tissue.